Calcium Antagonists and Experimental Atherosclerosis
Conclusion The role of organic calcium antagonists in prevention of atherosclerosis in animals is unsettled and appears to involve interaction with variables not yet defined. Interpretation should therefore be made with caution and is premature at this time. Conclusions concerning the effectiveness...
Gespeichert in:
| Veröffentlicht in: | Experimental biology and medicine (Maywood, N.J.) N.J.), 1989-03, Vol.190 (3), p.219-228 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 3 |
| container_start_page | 219 |
| container_title | Experimental biology and medicine (Maywood, N.J.) |
| container_volume | 190 |
| creator | Kjeldsen, Knud Stender, Steen |
| description | Conclusion
The role of organic calcium antagonists in prevention of atherosclerosis in animals is unsettled and appears to involve interaction with variables not yet defined. Interpretation should therefore be made with caution and is premature at this time. Conclusions concerning the effectiveness of calcium antagonists in suppressing atherosclerosis in humans must await the results of clinical trials with nifedipine and nicardipine (86). |
| doi_str_mv | 10.3181/00379727-190-42852a |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78885489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3181_00379727-190-42852a</sage_id><sourcerecordid>15592701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-95fe1954f69b48082b56f69169629040e8518c4ca5a45fbb2026f82347ed92833</originalsourceid><addsrcrecordid>eNqFkEtLw0AQgBdRaq3-AhFyEG_Rfcy-jqXUBxS86HnZbDc1JY-aTUD_vRsSe9TLzjLzzQzzIXRN8D0jijxgzKSWVKZE4xSo4tSeoDnhjKdMaH2K5gORDsg5ughhjzHhkooZmlEBQgCdI1jZ0hV9lSzrzu6aughdSGy9TdZfB98WlY_pMll2H75tgiuHtwiX6Cy3ZfBXU1yg98f12-o53bw-vayWm9QBlV2qee6J5pALnYHCimZcxD8RWlCNAXvFiXLgLLfA8yyjmIpcUQbSbzVVjC3Q3Tj30DafvQ-dqYrgfFna2jd9MFIpxUHpf0HCuaYSkwiyEXTxkND63Bzikbb9NgSbQar5lWqiVDNKjV030_g-q_z22DNZjPXbqW6Ds2Xe2toV4YgJKUEBRAyPWLA7b_ZN39bR3p-bfwAWzIsH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15592701</pqid></control><display><type>article</type><title>Calcium Antagonists and Experimental Atherosclerosis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kjeldsen, Knud ; Stender, Steen</creator><creatorcontrib>Kjeldsen, Knud ; Stender, Steen</creatorcontrib><description>Conclusion
The role of organic calcium antagonists in prevention of atherosclerosis in animals is unsettled and appears to involve interaction with variables not yet defined. Interpretation should therefore be made with caution and is premature at this time. Conclusions concerning the effectiveness of calcium antagonists in suppressing atherosclerosis in humans must await the results of clinical trials with nifedipine and nicardipine (86).</description><identifier>ISSN: 0037-9727</identifier><identifier>ISSN: 1535-3702</identifier><identifier>EISSN: 1535-3699</identifier><identifier>EISSN: 1525-1373</identifier><identifier>DOI: 10.3181/00379727-190-42852a</identifier><identifier>PMID: 2646642</identifier><identifier>CODEN: PSEBAA</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; Arteriosclerosis - physiopathology ; Arteriosclerosis - prevention & control ; Biological and medical sciences ; Blood Platelets - physiology ; Calcium - physiology ; Calcium Channel Blockers - therapeutic use ; Cardiovascular system ; Endothelium, Vascular - physiopathology ; flunarizine ; Humans ; Hyperlipidemias - physiopathology ; Medical sciences ; Miscellaneous ; Muscle, Smooth, Vascular - physiopathology ; nifedipine ; Pharmacology. Drug treatments ; reviews ; verapamil</subject><ispartof>Experimental biology and medicine (Maywood, N.J.), 1989-03, Vol.190 (3), p.219-228</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-95fe1954f69b48082b56f69169629040e8518c4ca5a45fbb2026f82347ed92833</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6774844$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2646642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kjeldsen, Knud</creatorcontrib><creatorcontrib>Stender, Steen</creatorcontrib><title>Calcium Antagonists and Experimental Atherosclerosis</title><title>Experimental biology and medicine (Maywood, N.J.)</title><addtitle>Proc Soc Exp Biol Med</addtitle><description>Conclusion
The role of organic calcium antagonists in prevention of atherosclerosis in animals is unsettled and appears to involve interaction with variables not yet defined. Interpretation should therefore be made with caution and is premature at this time. Conclusions concerning the effectiveness of calcium antagonists in suppressing atherosclerosis in humans must await the results of clinical trials with nifedipine and nicardipine (86).</description><subject>Animals</subject><subject>Arteriosclerosis - physiopathology</subject><subject>Arteriosclerosis - prevention & control</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - physiology</subject><subject>Calcium - physiology</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiovascular system</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>flunarizine</subject><subject>Humans</subject><subject>Hyperlipidemias - physiopathology</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Muscle, Smooth, Vascular - physiopathology</subject><subject>nifedipine</subject><subject>Pharmacology. Drug treatments</subject><subject>reviews</subject><subject>verapamil</subject><issn>0037-9727</issn><issn>1535-3702</issn><issn>1535-3699</issn><issn>1525-1373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLw0AQgBdRaq3-AhFyEG_Rfcy-jqXUBxS86HnZbDc1JY-aTUD_vRsSe9TLzjLzzQzzIXRN8D0jijxgzKSWVKZE4xSo4tSeoDnhjKdMaH2K5gORDsg5ughhjzHhkooZmlEBQgCdI1jZ0hV9lSzrzu6aughdSGy9TdZfB98WlY_pMll2H75tgiuHtwiX6Cy3ZfBXU1yg98f12-o53bw-vayWm9QBlV2qee6J5pALnYHCimZcxD8RWlCNAXvFiXLgLLfA8yyjmIpcUQbSbzVVjC3Q3Tj30DafvQ-dqYrgfFna2jd9MFIpxUHpf0HCuaYSkwiyEXTxkND63Bzikbb9NgSbQar5lWqiVDNKjV030_g-q_z22DNZjPXbqW6Ds2Xe2toV4YgJKUEBRAyPWLA7b_ZN39bR3p-bfwAWzIsH</recordid><startdate>19890301</startdate><enddate>19890301</enddate><creator>Kjeldsen, Knud</creator><creator>Stender, Steen</creator><general>SAGE Publications</general><general>Blackwell Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>M7Z</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19890301</creationdate><title>Calcium Antagonists and Experimental Atherosclerosis</title><author>Kjeldsen, Knud ; Stender, Steen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-95fe1954f69b48082b56f69169629040e8518c4ca5a45fbb2026f82347ed92833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Animals</topic><topic>Arteriosclerosis - physiopathology</topic><topic>Arteriosclerosis - prevention & control</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - physiology</topic><topic>Calcium - physiology</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiovascular system</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>flunarizine</topic><topic>Humans</topic><topic>Hyperlipidemias - physiopathology</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Muscle, Smooth, Vascular - physiopathology</topic><topic>nifedipine</topic><topic>Pharmacology. Drug treatments</topic><topic>reviews</topic><topic>verapamil</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kjeldsen, Knud</creatorcontrib><creatorcontrib>Stender, Steen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kjeldsen, Knud</au><au>Stender, Steen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Calcium Antagonists and Experimental Atherosclerosis</atitle><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle><addtitle>Proc Soc Exp Biol Med</addtitle><date>1989-03-01</date><risdate>1989</risdate><volume>190</volume><issue>3</issue><spage>219</spage><epage>228</epage><pages>219-228</pages><issn>0037-9727</issn><issn>1535-3702</issn><eissn>1535-3699</eissn><eissn>1525-1373</eissn><coden>PSEBAA</coden><abstract>Conclusion
The role of organic calcium antagonists in prevention of atherosclerosis in animals is unsettled and appears to involve interaction with variables not yet defined. Interpretation should therefore be made with caution and is premature at this time. Conclusions concerning the effectiveness of calcium antagonists in suppressing atherosclerosis in humans must await the results of clinical trials with nifedipine and nicardipine (86).</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>2646642</pmid><doi>10.3181/00379727-190-42852a</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0037-9727 |
| ispartof | Experimental biology and medicine (Maywood, N.J.), 1989-03, Vol.190 (3), p.219-228 |
| issn | 0037-9727 1535-3702 1535-3699 1525-1373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78885489 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Arteriosclerosis - physiopathology Arteriosclerosis - prevention & control Biological and medical sciences Blood Platelets - physiology Calcium - physiology Calcium Channel Blockers - therapeutic use Cardiovascular system Endothelium, Vascular - physiopathology flunarizine Humans Hyperlipidemias - physiopathology Medical sciences Miscellaneous Muscle, Smooth, Vascular - physiopathology nifedipine Pharmacology. Drug treatments reviews verapamil |
| title | Calcium Antagonists and Experimental Atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T02%3A39%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Calcium%20Antagonists%20and%20Experimental%20Atherosclerosis&rft.jtitle=Experimental%20biology%20and%20medicine%20(Maywood,%20N.J.)&rft.au=Kjeldsen,%20Knud&rft.date=1989-03-01&rft.volume=190&rft.issue=3&rft.spage=219&rft.epage=228&rft.pages=219-228&rft.issn=0037-9727&rft.eissn=1535-3699&rft.coden=PSEBAA&rft_id=info:doi/10.3181/00379727-190-42852a&rft_dat=%3Cproquest_cross%3E15592701%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15592701&rft_id=info:pmid/2646642&rft_sage_id=10.3181_00379727-190-42852a&rfr_iscdi=true |